The regulatory effects of angiotensin II (AngII) on its receptor subtypes, AT 1 and AT 2 , were studied using cultured bovine adrenal cells (BAC), which express both receptor subtypes, and PC12W and R3T3 cells, which express only AT 2 receptors. In BAC, AngII caused a decrease in AT 1 -and AT 2 -binding sites and their corresponding messenger RNAs (mRNAs), but with different kinetics. AT 1 -binding sites decreased by more than 50% within the first 3 h, whereas AT 1 mRNA started to decline after a lag period of 3 h. Both AT 2 -binding sites and mRNA remained stable within the first 6 h of AngII treatment. Then, AT 2 mRNA decreased rapidly with an apparent half-life of 2-3 h, whereas AT 2 -binding sites declined with an apparent halflife of about 16 h. Measurement of transcription rate and mRNA half-life by the [ 3 H]uridine-thiouridine method revealed that AngII reduced by 90% the rate of AT 1 transcription, but had no effect on AT 1 mRNA half-life, whereas it slightly reduced AT 2 transcription, but markedly reduced AT 2 mRNA stability. All of the effects of AngII on both AT 1 and AT 2 receptors were blocked by losartan, indicating that they were mediated exclusively through the AT 1 receptor. In PC12W cells, AngII was unable to modify AT 2 -binding sites or mRNA. Moreover, in BAC, [ 125 I]AngII was internalized through the AT 1 receptor, whereas occupancy of AT 2 receptors in either BAC or PC12W did not produce internalization of the hormone. These results indicate that AngII, through the AT 1 receptor, down-regulates both AT 1 and AT 2 , but by different mechanisms; AT1 receptor is regulated through internalization-degradation of the occupied receptor and inhibition of transcription, whereas AT2 receptor is regulated mainly by decreasing the stability of its mRNA. Moreover, the phorbol ester phorbol 12-myristate 13-acetate mimicked most of the effects of AngII in BAC and decreased both AT 2 -binding sites and mRNA on PC12W cells, indicating that the hormonal regulation of both AT 1 and AT 2 receptors is mediated through protein kinase C activation. (Endocrinology 138: [725][726][727][728][729][730][731][732][733] 1997) T HE OCTAPEPTIDE hormone angiotensin II (AngII) exerts a variety of actions in the brain, adrenal gland, and kidney (1). Recently, two AngII receptor subtypes, named AT 1 and AT 2 , were characterized in peripheral tissues and the brain on the basis of their sensitivity to sulfhydryl reducing agents and selective AngII receptor antagonists (2). AT 1 receptor is sensitive to sulfhydryl reducing agents and has a high affinity for losartan or DUP753, whereas AT 2 receptor is insensitive to sulfhydryl reducing agents and has a high affinity for the nonpeptide PD123319 and the peptide CGP42112A. Both AT 1 (3, 4) and AT 2 (5, 6) receptors have been cloned and shown to have the structural features of a putative seven-transmembrane domain receptor.
I]AngII was internalized through the AT 1 receptor, whereas occupancy of AT 2 receptors in either BAC or PC12W did not produce internalization of the hormone. These results indicate that AngII, through the AT 1 receptor, down-regulates both AT 1 and AT 2 , but by different mechanisms; AT1 receptor is regulated through internalization-degradation of the occupied receptor and inhibition of transcription, whereas AT2 receptor is regulated mainly by decreasing the stability of its mRNA. Moreover, the phorbol ester phorbol 12-myristate 13-acetate mimicked most of the effects of AngII in BAC and decreased both AT 2 -binding sites and mRNA on PC12W cells, indicating that the hormonal regulation of both AT 1 and AT 2 receptors is mediated through protein kinase C activation. (Endocrinology 138: 725-733, 1997) T HE OCTAPEPTIDE hormone angiotensin II (AngII) exerts a variety of actions in the brain, adrenal gland, and kidney (1) . Recently, two AngII receptor subtypes, named AT 1 and AT 2 , were characterized in peripheral tissues and the brain on the basis of their sensitivity to sulfhydryl reducing agents and selective AngII receptor antagonists (2) . AT 1 receptor is sensitive to sulfhydryl reducing agents and has a high affinity for losartan or DUP753, whereas AT 2 receptor is insensitive to sulfhydryl reducing agents and has a high affinity for the nonpeptide PD123319 and the peptide CGP42112A. Both AT 1 (3, 4) and AT 2 (5, 6) receptors have been cloned and shown to have the structural features of a putative seven-transmembrane domain receptor.
Several in vitro studies have shown by both radioligandbinding techniques (7) (8) (9) (10) and electron microscopy (11) that binding of AngII to its receptor initiates its internalization and sequestration. As only about 25% of the internalized receptors are recycled to the plasma membrane (10) , it has been suggested that degradation of the internalized receptor is the main mechanism by which AngII regulates its own receptor. However, as in most of the above studies the total number of AngII-binding sites was measured, the effect of the hormone on AT 1 and AT 2 receptors was not possible to determine. Recent studies indicate that in several cell types AngII is also able after several hours to decrease AT 1 messenger RNA (mRNA) levels (12) (13) (14) (15) , but the effects in vivo are less clear (16 -18) . Studies on the regulation of AT 2 receptor by AngII have been limited to studies of binding sites in two models with contradictory results. In cultured rat ovarian granulosa cells, which only express AT 2 sites (19) , AngII binding was down-regulated by cAMP derivatives, serum, and AngII (20) . In R3T3 cells, which selectively express AT 2 receptors, they appear to be down-regulated by growth factors, but are increased by AngII and nonpeptide-and peptide AT 2 -selective antagonists (21) .
In the present study, using two cell types, one expressing both receptor subtypes and the other expressing only AT 2 receptor, we address the following question. 1) What are the effects of AngII on AT 1 -and AT 2 -binding sites and mRNA? 2) Which receptor subtype is involved? 3) By which mechanism, transcriptional or posttranscriptional, does AngII regulate both receptor subtypes? ceutical Co., Wilmington, DE), and the peptide CGP42112 was a gift from Dr. M. De Gasparo (Ciba-Geigy, Basel, Switzerland). PC12W cells (22) and R3T3 cells (21) 
Cell culture
Bovine adrenal fasciculata cells (BAC) were prepared by sequential treatment of adrenal cortical slices with trypsin (0.15%) (23) . The cells were cultured in a chemically defined medium of DMEM/F12 (1:1) supplemented with NaHCO 3 (14 mm) and HEPES (10 mm) and containing gentamicin (20 g/ml), penicillin (100 U/ml), streptomycin (0.1 mg/ml), nystatin (100 U/ml), transferrin (10 g/ml), insulin (10 g/ml), and FCS (1%). On the second day of culture, the medium was removed and replaced with serum-free medium. More than 95% of both isolated and cultured cells expressed 3␤-hydroxysteroid dehydrogenase (data not shown), and acute stimulation with either corticotropin or AngII produced about 400 ng/10 6 cells⅐2 h cortisol, a specific marker of adrenal fasciculata cells, whereas production of aldosterone, the specific marker of adrenal glomerulosa cells, was less than 2 ng/10 6 cells⅐2 h. In both dose-response and time-course experiments, AngII was renewed every 12 h. In experiments in which AngII antagonists were used, they were added 15 min before AngII.
PC12W cells were grown in DMEM/F12 supplemented with antibiotics, 5% FCS, and 10% heat-inactivated horse serum. Cells were plated at a density of 1 ϫ 10 5 cells/cm 2 and cultured for 7-10 days at 37 C under a humidified atmosphere of 5% CO 2 . Subsequently, cells were cultured in DMEM/F12 supplemented with 2.5% calf serum, 6.25 g/ml insulin, 6.25 g/ml transferrin, 6.25 ng/ml selenium, and 1.25 mg/ml BSA. When they approached confluence, PC12W cells were used for radioligand binding assays. R3T3 cells were grown in DMEM/F12 supplemented with antibiotics and 10% FCS. Cells were plated at a density of 1.25 ϫ 10 5 cells/cm 2 and cultured for 5-7 days at 37 C. When they approached confluence, cells were cultured for 3-4 days in DMEM/F12 supplemented with 0.1% BSA.
Radioligand binding assay
AngII was radiolabeled by the Iodogen method and then purified on a diethylaminoethyl-trisacryl column (7) . The specific activity of the isolated monoiodinated AngII, as measured by self-displacement in a RRA, was 600 -900 Ci/mmol. CGP42112 was radiolabeled by the Iodogen method and then purified by HPLC using a C 18 Bondapak column (Millipore, Guyancourt, France) eluted with an acetonitrile gradient of 10 -60% in trifluoroacetic acid. The specific activity of the isolated monoiodinated peptide was 800-1000 Ci/mmol.
The receptor assay was performed using 12-well plates containing approximately 0.5 ϫ 10 6 cells/well. When cells were preincubated with unlabeled ligands, they were washed once with 1 ml 150 mm ice-cold NaCl containing 1% BSA (NaCl/BSA), ice-cold acidic glycine buffer (50 mm glycine and 150 mm NaCl, pH 3.0) for 3 min at 4 C and twice with NaCl/BSA to remove the membrane-bound ligand (13) . Binding was carried out for 2 h at room temperature (equilibrium conditions) in 0. Ϫ6 m AngII or 10 Ϫ7 m CGP42112. At the end of the incubation, the medium was removed, and the cells were washed three times with NaCl/BSA and then dissolved in 0.5 m NaOH-0.4% sodium deoxycholate. The radioactivity of the binding assays was measured in a ␥-counter.
RNA isolation and Northern blot analysis
Total RNA was isolated from cells by the method of Chomczynski and Sacchi (24) . For Northern blot analysis, total cytoplasmic RNA (15-40 g) was subjected to electrophoresis through 1% agarose gels containing 8% formaldehyde. RNA was then transferred to a Hybond-N membrane (Amersham, Les Ulis, France). Membranes with bound RNA were irradiated for 2 min by UV light and baked at 80 C to cross-link the RNA to the filters. Then, the filters were prehybridized for at least 2 h at 42 C in 50% formamide, 5 ϫ SCC (1 ϫ SCC ϭ 0.15 m NaCl and 0.015 m sodium citrate), 5 ϫ Denhart's solution, 0.5% SDS, 1% glycine, 50 mm NaPO 4 , and 0.25 mg/ml boiled salmon sperm DNA. Hybridization was carried out at 42 C overnight in hybridization buffer [50% formamide, 20 mm NaPO 4 (pH 6.5), 5 ϫ SCC, 1 ϫ Denhart's solution, 0.5% SDS, 10% dextran sulfate, and 0.1 mg/ml salmon sperm DNA], using either AT 1 cDNA (4) or AT 2 cDNA (6) as probe. Labeling of these probes in the presence of [␣-
32 P]deoxy-CTP was performed with a multiprime DNA labeling system (Amersham, Arlington Heights, IL). The blots were washed twice in 2 ϫ SCC buffer containing 0.1% SDS at room temperature for 15 min, once in 0.2 ϫ SCC containing 0.1% SDS at room temperature for 15 min, and finally in 0.2 ϫ SCC containing 0.1% SDS at 42 C for 5-10 min. The blots were exposed to Hyperfilm MP (Amersham) and analyzed by scanning densitometry using a preference HIT (Sebia, Paris, France). Equal loading of RNA samples was confirmed by photographing the ethidium bromide-stained membranes with Polaroid type 55 film (Polaroid, St. Albans, Hertfordshire, UK) and scanning the 28S RNA images on the photograph negatives.
RNA stability transcription rate
To measure the half-life of both AT 1 and AT 2 mRNAs, cells on the fourth day of culture were incubated for 8 h without or with AngII (10 Ϫ7 m). The medium was removed and replaced by fresh medium without or with AngII and containing actinomycin D (10 g/ml) or ␣-amanitin (40 g/ml). At these concentrations, the incorporation of [ 3 H]uridine into trichloroacetic acid-precipitable material after 2-h incubation was 3% and 16%, respectively. At the indicated times, AT 1 and AT 2 mRNAs were measured by Northern blot.
The RNA stability as well as the rate of transcription were also determined by the method of Johnson et al. (25) with slight modifications. In brief, cells on the fourth day of culture were incubated for 8 h in the absence or presence of AngII. Then, the medium was removed and replaced by fresh medium without or with AngII and containing 4-thiouridine (50 m, final concentration) and [ 3 H]uridine (3 Ci/l, final concentration). After 2 h, the medium was aspirated, the cells were washed three times with cold medium, and the RNA was extracted immediately by the method of Chomczynski and Sacchi (24) . The amount of total RNA was quantitated by absorbance at 260 nm, and the specific activity (disintegrations per min/g RNA) was calculated by counting an aliquot. One aliquot of the total RNA (ϳ40 g) was removed for Northern blot, and the remainder was used for affinity chromatography with mercurated agarose (Affi-Gel 501, Bio-Rad Laboratories, Richmond, CA) to purify newly synthesized RNA. The amount of this newly synthesized RNA as well as its specific activity were measured. For total unfractionated RNA, the same amounts (micrograms) were used for electrophoresis, whereas for the newly synthesized RNA, the same amount of radioactivity was used. The membranes containing both total and newly synthesized RNA were hybridized successively with AT 2 and AT 1 32 P-labeled cDNA. The autoradiographs were quantitated by densitometry scanning. The rate of transcription and the half-life were calculated exactly as described by Johnson et al. (25) .
The transcription rate was determined by the ratio of the optical densities of newly synthesized RNA in control and treated cells. The half-life of the specific transcripts was calculated by the following equation: e Ϫkt ϭ [A Ϫ (B ϫ C)/A], where A is the optical density of unfractionated RNA, B is the specific activity (optical density per dpm) of newly synthesized RNA, C is the amount (disintegrations per min) of RNA used in A, k is the first order rate constant of degradation (t 1/2 of transcript), and t is the time (2 h).
Results

Characterization of AngII receptor subtypes and binding sites mRNAs in BAC PC12W
Binding studies using [ 125 I]AngII have shown that BAC contain about 10 5 sites/cell of a single class of high affinity binding sites (K d ϭ ϳ1 nm) (10) . However, the results presented in Fig. 1 show that these cells express both AT 1 and AT 2 receptor subtypes, because at saturating concentrations, CGP42112, a specific ligand of the AT 2 receptor, reduced by 20% the binding of [ 125 I]AngII, whereas DUP753 or losartan, a specific ligand of AT 1 receptor, reduced it by 80%. Moreover, in each experimental condition, the remaining binding was completely inhibited by increasing concentrations of the other ligand. BAC also expressed both receptor mRNAs: a single AT 1 transcript of 3.3 kilobases (kb) and two AT 2 transcripts of 3.8 and 2.3 kb. On the other hand, PC12W expressed only AT 2 -binding sites and mRNA. Similarly, R3T3 cells, as previously reported (21, 26) , expressed only AT 2 -binding sites and a single transcript of 3.2 kb (data not shown).
Effect of AngII on AT 1 -and AT 2 -binding sites and mRNAs in BAC
Treatment of cells with increasing concentrations of AngII caused a dose-dependent inhibition of AT 1 and AT 2 binding sites and mRNAs (Fig. 2) . The maximal inhibitory effect was observed at 10 Ϫ7 m, but the IC 50 for AT 1 -and AT 2 -binding sites and AT 1 mRNA (3 Ϯ 0.4 ϫ 10 Ϫ9 m) was significantly higher (P Ͻ 0.05) than that for AT 2 mRNA (2.8 Ϯ 0.3 ϫ 10 Ϫ10 m). It must be noted that the former IC 50 values are similar to the K d and ID 50 for cortisol secretion (27) .
However, the most striking differences were observed in the time-course effects of AngII on the four parameters (Fig.  3) . AT 1 -binding sites decreased very rapidly, and by 3 h, more than 50% of the surface receptors disappeared. The half-life of these receptors calculated from the experimental points of the first 6 h was about 2 h. Thereafter, a steady state of about 30% of the control remained during the next 18 h. In contrast, the effects of AngII on AT 1 mRNA levels appeared after a lag period of about 3 h and were less marked. The calculated half-life after the initial lag period was about 8 h. The effects of AngII on AT 2 -binding sites were not significant during the first hours of treatment. Thereafter, the surface receptor declined with an apparent half-life of 14 -16 h. Similarly, the effects on AT 2 mRNA were not significant during the first 6 h of treatment, but then the levels dramatically decreased, with an apparent half-life of 2 h.
The inhibitory effects of AngII on both receptor subtypes, binding sites, and mRNAs, were reversible, but the kinetics of recovery were different for AT 1 ( Fig. 4) . Thus, most AT 1 -binding sites and mRNA were recovered within the first 24 h of hormone withdrawal, whereas recovery of AT 2 -binding sites and mRNA required more than 3 days.
Receptor subtype involved in the regulation of AT 1 and AT 2 receptors by AngII
To investigate which receptor subtype was involved in the effects of AngII on AT 1 and AT 2 receptors described above, BAC were treated with AngII in the absence or presence of the AT 1 antagonist DUP753 or the AT 2 -specific ligand CGP42112 for 1 day, and at the end of the experimental period, AT 1 -and AT 2 -binding sites and mRNAs were measured (Fig. 5) . Neither DUP753 nor CGP42112 alone had any effect on the four parameters studied. However, DUP753, but not CGP42112, completely blocked the effects of AngII on both receptor subtypes, binding sites, and mRNA. These findings indicate that the AngII-induced down-regulation of both receptor subtypes was exclusively mediated through AT 1 receptor. In favor of this hypothesis are the results presented in Table 1 , showing that in PC12W and R3T3 cells, which express exclusively AT 2 receptors, AngII had an effect on AT 2 -binding sites and mRNA, whereas in BAC, it markedly reduced both parameters.
The lack of effect of AngII on AT 2 -binding sites in the presence of DUP753 in BAC and of AngII alone in PC12W and R3T3 cells might be due to either a lack of internalization of the occupied receptor or rapid recycling of the internalized receptor. To investigate the first hypothesis, both BAC and PC12W cells were incubated with [
125 I]AngII (10 Ϫ9 m) in the absence or presence of DUP753 or CGP42112, and the total membrane-bound (released by acidic washing) and internalized (acid-resistant) hormone levels were determined (Table 2). In BAC incubated with [
125 I]AngII alone, approximately 60% of the hormone was internalized. However, in the presence of CGP42112, which blocks the binding of [ 125 I]AngII to AT 2 receptors, the internalized hormone increased to 75% of the total amount bound. In contrast, in the presence of DUP753, which blocks the binding of [
125 I]AngII to AT 1 receptor, no internalization was observed. Similarly, in PC12W cells, the hormone was not internalized regardless of the experimental condition.
Effect of protein kinase C activation on AngII-binding sites and mRNA in BAC and PC12W cells
In BAC, AngII has been shown to activate the phosphoinositide pathway through the AT 1 receptor (27) , whereas in PC12W cells, AngII is unable to activate it (28) . To elucidate whether activation of protein kinase C (PKC) was involved in the regulation of AT 1 -and AT 2 -binding sites and mRNAs, both BAC and PC12W cells were treated for 2 days with either AngII or PMA. The results (Fig. 6) show that in both cell types, PMA reduced the number of AT 2 -binding sites and the level of mRNA. Moreover, in BAC, the effects of AngII and PMA were similar on all parameters studied, except on AT 1 -binding sites, for which the effects of PMA were less marked than those produced by AngII, probably because PMA was unable to induce the internalization and degradation of AT 1 receptors.
Half-life of AT 1 -and AT 2 -binding sites
The different kinetics in the decline in the numbers of AT 1 -and AT 2 -binding sites in BAC after AngII treatment could be related to a difference in the half-lives of these two receptors. To measure them, BAC were incubated with cycloheximide (10 g/ml) at a concentration that blocked more than 95% of protein synthesis (data not shown) for 12 h, and at different times AT 1 -and AT 2 -binding sites were evaluated. The results (Fig. 7) show that the half-lives of AT 1 and AT 2 were similar (14.8 Ϯ 1.5 and 16.9 Ϯ 2 h, respectively). For comparison, in the same figure are shown the effects of AngII and AngII plus cycloheximide on AT 1 -and AT 2 -binding sites. Clearly, the results show that the different effects of the hormone on these two receptors are not related to a difference in their half-lives and that cycloheximide was unable to block the rapid effects of AngII on AT 1 -binding sites.
Effects of AngII on AT 1 and AT 2 mRNA stability and gene transcription
The inhibitory effects of AngII on AT 1 and AT 2 mRNAs could be due to either an increase in the rate of degradation and/or a decrease in the rate of transcription. To evaluate the half-lives of the two mRNAs, control and AngII-treated cells (8 h) were incubated in the presence of actinomycin D (10 g/ml), and the levels of both mRNAs were evaluated by Northern blot at several times. In the presence of actinomycin D, the half-life of AT 1 mRNA was similar in control and AngII-treated cells (8.1 Ϯ 1.1 and 8.2 Ϯ 1.5 h, respectively; n ϭ 3; Fig. 8 ). The half-life of AT 2 mRNA in control cells was about 18 h, which was approximately 8-fold longer than the calculated half-life between 8 -12 h after the addition of AngII (Fig. 3) . However, when the 8-h AngII-treated cells were treated with actinomycin D, there was a small increase in the level of AT 2 mRNA within the first 2 h. Thereafter, the level of AT 2 mRNA declined with an apparent half-life similar to that in control cells. Thus, it appears as if actinomycin D itself may cause a marked stabilization of the AT 2 mRNA. Similar results were obtained when ␣-amanitin (50 g/ml) was used as transcription inhibitor (data not shown).
To evaluate the effects of AngII on the rate of transcription of the AT 1 and AT 2 genes, we used the method described by Johnson et al. (25) , which also allows evaluation of the halflife of mRNA (Table 3 and Fig. 9 ). AngII markedly reduced (by 90%) the transcription of AT 1 mRNA. It should be noted that similar results were obtained for AT 1 mRNA half-life using this method and actinomycin D (see above). Moreover, further analysis of the data, as proposed by Johnson et al. (25) , showed that the assumption of steady state on which the determination of half-life depends was fulfilled. The effects of AngII on AT 2 transcription and AT 2 mRNA half-life were different, i.e. it decreased the rate of transcription by about 30% and the half-life by more than 80%. However, because in this case steady state conditions were lacking, the rate of transcription was probably underestimated, whereas the half-life might have been overestimated.
Effects of protein and mRNA synthesis inhibition on AngIIinduced down-regulation of AT 1 and AT 2 mRNA levels
As the effects of AngII on both receptor subtype mRNA levels were observed after a lag period, we hypothesized that they probably required new protein and/or mRNA synthesis. In the experiments presented in Fig. 10 , cells were treated for 12 h with cycloheximide or actinomycin D in the absence or presence of AngII. The antibiotics were added 10 min before AngII. Cycloheximide alone had very small and nonsignificant effects on AT 1 or AT 2 mRNA levels, but significantly reduced (P Ͻ 0.02) both AT 1 -and AT 2 -binding sites (see also Fig. 3 ). Actinomycin D had no effect on either AT 1 -or AT 2 -binding sites, but, as expected (see Fig. 8 ), reduced both AT 1 and AT 2 mRNA levels (P Ͻ 0.02). More important cycloheximide almost completely abolished the negative effects of the hormone on both AT 1 and AT 2 mRNA levels, but 
Discussion
The major findings of the present study are that AngII down-regulates both AT 1 and AT 2 mRNAs and binding sites, but with different kinetics and through different mechanisms, and that these effects are mediated exclusively through AT 1 receptor subtype. These conclusions are supported by the observation that in BAC, which express both receptor subtypes, the effects of AngII were blocked by AT 1 antagonist, whereas in PC12W and R3T3 cells, which express only AT 2 receptor, AngII had no effect on AT 2 mRNA levels or binding sites.
Many in vivo and in vitro studies have shown that one of the most potent factors affecting AngII receptor protein, as determined by early ligand binding studies (measuring both AT 1 and AT 2 receptors), is AngII itself (7) (8) (9) (10) 29) . In some of these studies it was demonstrated that rapid sequestration and internalization of the hormone-receptor complex were two of the mechanisms responsible for the down-regulation (8 -11) . This hormone-induced internalization of the receptor has been recently confirmed using cells stably transfected with both AT 1a and AT 1b rat cDNAs (30 -33) . In some studies it was shown that internalization of the receptor is independent of agonist-activated transduction and that the molecular determinants for agonist-induced receptor internalization are located in a short domain on the cytoplasmic tail (33) . In contrast with these negative effects of AngII on its own receptor observed in most of its target tissue in several species, contradictory results have been reported concerning the regulation of the AngII receptor in rat adrenals. An increase in total AngII receptor has been observed after nephrectomy (34) or potassium loading (35) , which decrease plasma AngII levels, but also after sodium depletion in rats (36) , which increases plasma AngII levels. Similarly, constant infusion of low doses of AngII also increases the number of adrenal AngII receptors (37) , whereas at high concentrations the hormone reduced its receptor in adrenal as well as other target tissues (38) . The reasons for these apparently contradictory results are not clear, but may be related to a different regulation of AT 1 and AT 2 receptors expressed in rat adrenals (2) and/or to the fact that in rats and mice, but not in other species, AT 1 receptors are encoded by different genes (39, 40) , which have different patterns of expression and regulation (see below).
Using specific probes for AT 1 -and AT 2 -binding sites and mRNAs, we have been able to evaluate more precisely the kinetics and mechanisms by which AngII regulates both receptor subtypes in BAC. AngII induced a dose-and timedependent decrease in AT 1 -binding sites. At maximal concentrations, the initial apparent half-life of AT 1 receptor was about 2 h, which was about 8-fold shorter than that observed in control cells in the presence of cycloheximide. As the AT 1 mRNA levels during the first 3 h of AngII treatment were decreased by less than 10%, and the AngII-receptor complex (exclusively AT 1 receptor; see below) was internalized, the initial rapid decline in AT 1 -binding sites is probably due to the internalization-degradation process of occupied AT 1 receptor. In addition to this rapid effect, the hormone thereafter caused a decrease in AT 1 receptor mRNA levels that was also time and dose dependent and, due to an inhibition of the transcription rate, produced no apparent change in the AT 1 mRNA half-life. Similarly, in normal human cultured adrenal fasciculata cells (13) and the human tumor adrenal cell line H295 (41), AngII also reduced AT 1 mRNA levels.
Regulation of AT 1 mRNA has been studied mainly in the rat tissue, and some of the results are contradictory. Sodium depletion, which increases plasma AngII levels, has been reported to either have no effect on AT 1a or AT 1b mRNA levels in several tissues, including the adrenal (17), or to increase AT 1b mRNA in the brain (42) , whereas AT 1 receptor antagonist administration to intact rat decreases the levels of both mRNAs in aorta and brain and that of AT 1b in adrenal (16, 17) . On the other hand, bilateral nephrectomy decreases AT 1a mRNA levels in brain, liver, and adrenal, but increases those of AT 1b in adrenals (16, 18) , whereas infusion of AngII increased total AT 1 mRNA in adrenal, but had no effect in other tissues (16) . In contrast, in cultured rat glomerular mesangial cells (12) and in cultured vascular smooth muscle cells (14, 15) , AngII markedly reduced AT 1 mRNA levels. Thus, it appears that in the rat, the two AT 1 receptor mRNAs are regulated differently, but no clear-cut conclusion can be drawn.
AngII also down-regulated both AT 2 -binding sites and mRNA, but with different kinetics and through different mechanisms than those involved in the regulation of the AT 1 receptor. In BAC, occupancy of only AT 2 by either AngII in the presence of the AT 1 antagonist DUP753 or by CGP42112 had no effect on AT 2 -binding sites and mRNA. Similarly, in PC12W and R3T3 cells, which contain only AT 2 receptors (21, 22) , AngII was unable to modify AT 2 -binding sites and mRNA. Moreover, no internalization of [ 125 I]AngII was observed when BAC were incubated with the labeled hormone in the presence of DUP753 or when PC12W cells were incubated with the labeled hormone alone. These results confirm previous studies showing the lack of agonist-induced AT 2 internalization (33, 43) and demonstrate that the effects of AngII on AT 2 receptor are exclusively mediated through the AT 1 receptor. Moreover, the half-life of AT 2 receptor was similar in cells treated with cycloheximide and those treated with AngII, suggesting that the hormone had no significant effect on the turnover of AT 2 protein. Indeed, our results clearly show that AngII after a lag period of 6 -8 h dramatically decreased AT 2 mRNA levels, mainly by reducing its half-life from 18 h in control cells to about 2 h in AngII-treated cells. These observations suggest that AngII induced the synthesis of labile destabilizing factor(s), which degrades the AT 2 mRNA. In favor of this hypothesis is the fact that both cycloheximide and actinomycin D block the effects of AngII on AT 2 mRNA levels. Unfortunately, examination of the rate of decay of AT 2 mRNA in control and AngII-treated cells in the presence of two different transcription inhibitors did not reveal a difference in the stability of the message, most likely because the transcription inhibitor blocked transcription of the labile destabilizing factors. Similar unexpected results have been reported recently concerning the LH/hCG receptor in rat granulosa cells (44) . The calculated half-life of AT 2 mRNA by the [ 3 H]uridine-thiouridine method, showing a reduced half-life in AngII-treated cells, favors the above hypothesis. In addition, AngII appears to decrease the rate of transcription of the AT 2 gene, but these small changes in transcription cannot explain the rapid and marked changes in AT 2 mRNA levels.
Studies concerning the regulation of AT 2 -binding sites by AngII in other cell types are sparse, and some of the results are conflicting. In rat granulosa cells (20) , which contain only AT 2 receptor subtypes (19) , AngII reduced the number of AT 2 -binding sites. However, whether this decrease corresponds to receptor loss or to occupancy by the hormone added to the culture is unknown, as in these studies binding measurements were performed in cells not washed with acidic buffer to remove the bound hormone. In cultured bovine thecal cells, which also express only AT 2 receptor, AngII had no effect on these receptors (45) . In contrast, in R3T3 fibroblasts that selectively express AT 2 receptors at confluence, it has been reported that AngII as well as its peptide (Sar 1 ,Ala 8 -AngII) and nonpeptide (PD123319) antagonists increase AT 2 receptor number 2-to 3-fold (21) , but decrease by about 25% the levels of AT 2 mRNA (26). These surprising results, which are opposite those we observed in BAC, PC12W, and R3T3 cells, are difficult to explain. It must be pointed out that this lack of effect of AngII was observed using different cell passages. Moreover, under the same experimental conditions, both AT 2 -binding sites and mRNA in PC12W and R3T3 cells were down-regulated by 10% FCS and basic fibroblast growth factor (our unpublished data), as previously shown in rat vascular smooth muscle cells (46) and R3T3 cells (21, 26) .
In all cells studied, AT 1 receptors are coupled to the phosphoinositide pathway and, therefore, to PKC activation (2-4), whereas the intracellular effectors of AT 2 are still not well defined (2, 5, 6, 27, 43) . Our results show that activation of PKC by PMA mimicked most of the effects of AngII in BAC (except on AT 1 -binding sites) and reduced both the number of AT 2 -binding sites and mRNA levels in PC12W cells. These findings indicate that AngII regulates its own receptors mainly through PKC. Moreover, the effects of AngII on AT 1 and AT 2 mRNA required new mRNA and protein synthesis, as they were blocked by both actinomycin D and cycloheximide. In contrast, the rapid effects of AngII on AT 1 -binding sites were not blocked by any of these antibiotics.
In conclusion, the present findings identify two components of AngII-induced down-regulation of AT 1 receptors: rapid internalization-degradation of the occupied receptors and reduction of AT 1 mRNA levels due to an inhibition in the rate of transcription. Both of these effects require occupancy of the AT 1 receptor. They also show a unique cross-regulation of the AT 2 receptor in which AngII, exclusively through the AT 1 receptor, caused a decrease in AT 2 receptor mainly by decreasing AT 2 mRNA stability.
